| 9/10/2021 |
Global Genetic Testing Services Market to Record Impressive Growth, to Surpass US$ 64.1 Billion by 2025 |
latestmarketreports.com |
... has studied the global genetic testing services market with detailed segmentation on the basis of test types, service providers, applications and key regions.Test types- Prenatal Testing- New Born Screening- Predictive and Presymptomatic Testing- Pharmacogenomic Testing - OthersService providers- Hospital-based Laboratories- Diagnostic Laboratories- Specialty Clinics- OthersApplications- Oncology- Infectious Diseases- Autoimmune Diseases- OthersKey Regions- North America- Europe- Asia Pacific- Latin America- Middle East & Africa“This taxonomy prepared is ... |
| 9/3/2021 |
New Born Screening Market Soaring Demand Assures Motivated Revenue Share During 2020 to 2025 |
express-press-release.net |
... testing services market with detailed segmentation on the basis of test types, service providers, applications and key regions. Test types Service providers Applications Key Regions - Prenatal Testing - New Born Screening - Predictive and Presymptomatic Testing - Pharmacogenomic Testing - Others - Hospital-based Laboratories - Diagnostic Laboratories - Specialty Clinics - Others - Oncology - Infectious Diseases - Autoimmune Diseases - Others - North America - Europe - Asia Pacific - Latin America - Middle East & Africa Need more information about Report Methodology? Click here- https ... |
| 8/23/2021 |
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid Treated Oncology Patients |
wiley.com |
Abstract BackgroundSeveral opioids have pharmacogenomic associations impacting analgesic efficacy. However, germline pharmacogenomic testing is not routinely incorporated into supportive oncology. We hypothesized that CYP2D6 profiling would correlate with opioid prescribing and hospitalizations. Patients and MethodsWe analyzed 61,572 adult oncology patients from 2012-2018 for opioid exposures. CYP2D6 metabolizer phenotype (ultra-rapid [UM], normal metabolizer [NM], intermediate [IM], or poor [PM]), the latter two of which may cause inefficacy of ... |
| 8/23/2021 |
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid Treated Oncology Patients - PubMed |
National Institutes of Health |
... Chicago, Chicago, IL, USA. 5 Department of Pathology, University of Chicago Medical Center and Biological Sciences, Chicago, IL, USA. PMID: 34423496 Format AbstractBackground: Several opioids have pharmacogenomic associations impacting analgesic efficacy. However, germline pharmacogenomic testing is not routinely incorporated into supportive oncology. We hypothesized that CYP2D6 profiling would correlate with opioid prescribing and hospitalizations.Patients and methods: We analyzed 61,572 adult oncology patients from 2012-2018 for opioid exposures. CYP2D6 ... |
| 8/19/2021 |
Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report |
biomedcentral.com |
... to ondansetron, prochlorperazine, and metoclopramide followed by persistent focal dystonia. A similar family history was reported in her siblings and her father to prochlorperazine, drugs all metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme. Pharmacogenomic testing indicated the patient was heterozygous for the intermediate metabolizer 41 allele (CYP2D6 2988G A, NM_000106.6:c.985+39G A, rs28371725). Her father was homozygous for this CYP2D6 41 allele, and consequently, her siblings ... |
| 8/18/2021 |
Genetic Testing Market - Expected Growth of USD 5.39 billion| Segmentation based on Product, Application & Geography| Technavio |
tncontentexchange.com |
... and the market's growth momentum will accelerate at a CAGR of 12%? This report provides a detailed analysis and extensively covers market segmentation by product (equipment and consumables), application (predictive and diagnostic testing and pharmacogenomic testing ), and geography (North America, Europe, Asia, and ROW). The genetic testing market report also offers information on several market vendors Some of the major highlights from Technavio's Genetic Testing Market B2B Market report: - The ... |
| 8/18/2021 |
Genetic Testing Market - Expected Growth of USD 5.39 billion| Segmentation based on Product, Application & Geography| Technavio |
PR Newswire |
... and the market's growth momentum will accelerate at a CAGR of 12%?This report provides a detailed analysis and extensively covers market segmentation by product (equipment and consumables), application (predictive and diagnostic testing and pharmacogenomic testing ), and geography ( North America , Europe , Asia , and ROW). The genetic testing market report also offers information on several market vendorsTechnavio has announced its latest market research report titled Genetic Testing Market by Product ... |
| 7/31/2021 |
Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting |
rtihs.org |
... becoming increasingly feasible with the availability of more affordable genetic sequencing technologies and successful genetic associations with phenotypes, especially in the pharmacogenomic field. Although substantial progress has been made to ensure successful uptake of pharmacogenomic testing in the clinical setting already, many challenges still remain for sustainable implementation. The importance of pharmacogenomic information in patient care, identifying key barriers, and proposed solutions for advancing pharmacogenomic implementation will be discussed. The ... |
| 4/26/2021 |
AccessDx Laboratory Teams With Jase Health to Embed Lab Processes Into Electronic Health Records |
genomeweb.com |
... data integration firm Jase Health to embed lab processes into clinical workflows within major electronic health records systems.AccessDx Lab, a Houston-based CAP/CLIA diagnostic lab, offers molecular services including COVID-19 testing, pharmacogenomic testing , cancer genomic screening, and respiratory pathogen panels. Jase Health, of Johnston, Iowa, integrates outside technologies into EHR products from Cerner, Epic Systems, Meditech, Athenahealth, Allscripts Healthcare Solutions, and others.The firms said that the ... |
| 4/13/2021 |
Global Genetic Testing Market Report 2021-2025: Newborn, NIPT, Predictive, Oncology, DTC, Others - COVID-19 Crowds Out Other Services |
Globe Newswire |
... too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life, and new problems for the industry.Predictive Diagnostics? Pharmacogenomic Testing ? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts ... |
| 4/1/2021 |
The Building Blocks of a Pharmacogenomic Program |
aacc.org |
... medications may be based on population data, but individuals vary significantly in the way they respond. Only about 50%–75% of individuals taking a medication will have the intended response ( 2 ). The goals of pharmacogenomic testing are to shorten the trial-and-error period, optimize medication dosage, and reduce the risk of side effects.It’s important to note that pharmacogenomic information is still relatively new and somewhat limited. Genetics ... |
| 3/24/2021 |
US Genetic Testing Market Size, Share, Industry Analysis Report by Trends, COVID-19 Impact, Top Players are Ambry Genetics, Illumina, Inc., IntegraGen, BGI, Roche Diagnostics |
heraldkeeper.com |
... expression, or through biochemical analysis to measure specific protein output. There are various type of genetic test are available to determine disorders such as predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing , nutrigenomics and others. Among all, newborn testing can identify genetic disorders early in life so treatment can be started as early as possible.Get Sample of This [email protected] https://brandessenceresearch.com/requestSample/PostId/1362 Sample ... |
| 3/24/2021 |
Genetic Testing Market Set for Rapid Growth, To Reach Around USD 23143.42 Million by 2027 with the CAGR of 11.5% |
heraldkeeper.com |
... expression, or through biochemical analysis to measure specific protein output. There are various type of genetic test are available to determine disorders such as predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing , nutrigenomics and others. Among all, newborn testing can identify genetic disorders early in life so treatment can be started as early as possible.Genetic testing market report is segmented on the basis of test ... |
| 3/16/2021 |
Genome-Guided Reassurance |
Physicians Weekly |
Genome-Guided ReassuranceMar 16, 2021 As mentioned above, we aim to delineate the available pharmacogenomic information related to fluorouracil (FU) and DPYD, an association pair that regularly raises questions regarding the application of pharmacogenomic testing .Based on the available information by the WHO, cancer remains the second leading cause of death worldwide, with colorectal cancer affecting approximately 1.8 million patients.On the contrary, the rather crucial issue of the toxicity of ... |
| 3/16/2021 |
Genome-Guided Reassurance |
thedoctorspost.com |
As mentioned above, we aim to delineate the available pharmacogenomic information related to fluorouracil (FU) and DPYD, an association pair that regularly raises questions regarding the application of pharmacogenomic testing .Based on the available information by the WHO, cancer remains the second leading cause of death worldwide, with colorectal cancer affecting approximately 1.8 million patients.On the contrary, the rather crucial issue of the toxicity of the antineoplastic treatment has not been ... |
| 3/4/2021 |
Utilizing Pharmacogenomics Information to Guide AML Treatment |
pharmacytimes.com |
Utilizing Pharmacogenomics Information to Guide AML Treatment 2021-03-03 18:57:00 Katelyn Yamartino, PharmD; and Lisa Holle, PharmD, BCOP, FHOPA, FISOPP Pharmacogenomic testing plays a large role in selecting appropriate therapy for the treatment of acute myeloid leukemia (AML), a hematologic malignancy characterized by clonal expansion of myeloid hematopoietic precursors in the bone marrow and peripheral blood. 1 There are specific treatment options patients may qualify for depending on the cytogenetic or ... |
| 3/1/2021 |
Milestones in Payer Coverage Set to Expand Pharmacogenomic Testing |
blogspot.com |
... test reimbursement from this past summer and their implications for the field moving forward.The Medicare Administrative Contractors (MACs) participating in the Molecular Diagnostic Services ( MolDx) program released their final local coverage determinations (LCDs) pharmacogenomic testing in July/August.PharmGKB and CPIC view these as significant advances because of the large number of US Medicare patients impacted. Further, the LCDs state PGx testing as reasonable and necessary when medications have ... |
| 2/16/2021 |
ACCP Oncology Genomics Certificate Program Registration is Open |
accp.com |
... interpret molecular testing results and develop a therapeutic plan. Educate patients and health care professionals about the principles of clinical pharmacogenomics, including clinical utility, cost-effectiveness, reimbursement, and ethical, legal, and social implications of pharmacogenomic testing . CompetenciesDomain 1 – Foundational Knowledge 1.1 Learner (Learner) - Develop, integrate, and apply knowledge from the pharmacogenomic and clinical sciences to evaluate the scientific literature, explain drug action, solve therapeutic problems, and advance population ... |
| 1/29/2021 |
Genetic screening before prescribing could benefit millions |
eurekalert.org |
Genetic screening before prescribing could benefit millions Peer reviewed - Simulation/modelling Print E-MailFour million UK patients could benefit annually from genetic testing before being prescribed common medicines, according to new research from the University of East Anglia (UEA) in collaboration with Boots UK and Leiden University (Netherlands).Researchers looked through 2019 NHS dispensing data across the UK to see how many patients are started on new prescriptions each ... |
| 1/29/2021 |
Genetic screening before prescribing could benefit millions |
medicalxpress.com |
by University of East Anglia Credit: Pixabay/CC0 Public DomainFour million UK patients could benefit annually from genetic testing before being prescribed common medicines, according to new research from the University of East Anglia (UEA) in collaboration with Boots UK and Leiden University (Netherlands).Researchers looked through 2019 NHS dispensing data across the UK to see how many patients are started on new prescriptions each year that could be ... |